Eisai Co., Ltd. and Biogen Inc. announced an update on the ongoing regulatory review of the Marketing Authorization Application for lecanemab as a treatment for early AD (mild… read more.
Radiation from imaging could lead to lung, breast and other future cancers, with 10-fold increased risk for babies CT scans may account for 5% of all cancers annually,… read more.
A study led by researchers in the University of Florida College of Pharmacy has found that a pair of popular glucose-lowering medications may have protective effects against the… read more.
AbbVie announced that the EMA’s Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion recommending the approval of upadacitinib (Rinvoq 15 mg, once daily) for… read more.
The study, published in the journal Addiction and funded by Cancer Research UK, looked at survey data on vaping habits in England, Wales and Scotland before and after… read more.
Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. announced that the FDA has accepted its supplemental Biologics License Application (sBLA) for Ajovy (fremanezumab-vfrm) to expand the… read more.
Prescribed burns literally fight fire with more fire. Often referred to as a “beneficial fire,” they target areas at risk for wildfires and burn away material that could… read more.
Complications during pregnancy (or adverse pregnancy outcomes), like gestational diabetes and newly developed high blood pressure, act as nature’s stress test and may uncover an individual’s risk for… read more.
PDS Biotechnology Corporation, a late-stage immunotherapy company focused on transforming how the immune system targets and kills cancers, today announced that preclinical immune response data with a novel… read more.
NICE (UK): burosumab is recommended, within its marketing authorisation, for treating X‑linked hypophosphataemia (XLH) with radiographic evidence of bone disease in children aged 1 year and over, and… read more.
Patients with depression who received the Moodivate app saw clinically meaningful reductions in their symptoms that were twice those achieved with standard-of-care therapy in a clinical trial conducted… read more.
The UK pedigree dog population shrank by a yearly decline of 0.9% between 1990 and 2021, according to research published in Companion Animal Genetics and Health. The study… read more.
If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.
You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.
